|1.||Tselepis, Alexandros D: 21 articles (09/2014 - 12/2002)|
|2.||Koenig, Wolfgang: 18 articles (01/2015 - 10/2004)|
|3.||Ballantyne, Christie M: 17 articles (08/2015 - 02/2004)|
|4.||McConnell, Joseph P: 16 articles (03/2015 - 05/2004)|
|5.||Nelson, Jeanenne J: 16 articles (01/2012 - 01/2005)|
|6.||Wolfert, Robert L: 11 articles (03/2014 - 01/2002)|
|7.||Cushman, Mary: 10 articles (07/2015 - 05/2008)|
|8.||Macphee, Colin H: 10 articles (02/2015 - 06/2002)|
|9.||Zalewski, Andrew: 10 articles (05/2011 - 05/2005)|
|10.||Hoogeveen, Ron C: 8 articles (08/2015 - 02/2004)|
11/01/2007 - "After adjustment for baseline characteristics, patients in higher quartiles of Lp-PLA2 remained at significantly greater risk for the composite of cardiovascular death, MI, coronary revascularization, UA, or stroke (P<0.001 for trend, adj HR 1.41, 95% CI 1.17 to 1.70, for patients in 4th versus 1st quartile). "
01/01/2015 - "This study revealed the association of Lp-PLA2 mass with ICAS in stroke-free hypertensive patients in Chinese population. "
04/01/2014 - "The objectives of the study were to compare lipoprotein-associated phospholipase A2 (Lp-PLA2) levels in a prospective cohort including both ischemic and hemorrhagic strokes at the hyperacute phase, and to investigate if these levels were associated with stroke severity. "
01/01/2014 - "Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the Northern Manhattan Study."
02/01/2012 - "We aimed to investigate Lp-PLA2 in t-PA-treated stroke patients and to study its relationship with early outcome. "
07/01/2015 - "Lp-PLA2 mass and activity were measured at baseline in 5456 participants in the Multi-Ethnic Study of Atherosclerosis. "
03/01/2014 - "This study was conducted to describe the distribution of Lp-PLA2 in a cohort of human immunodeficiency virus (HIV)-infected adults and to determine associations between Lp-PLA2, cardiometabolic risk factors, and subclinical atherosclerosis in this population. "
12/01/2013 - "Further, a growing number of preclinical and genetic studies support a causal role for Lp-PLA2 in atherosclerosis. "
07/01/2013 - "We assessed Lp-PLA2 activity in 10,687 Atherosclerosis Risk in Communities (ARIC) Study participants and followed them a median of 8.3 years (from 1996-98 through 2005) for VTE occurrence (n=226). "
01/01/2013 - "With regard to the potential values of Lp-PLA(2) in risk stratification, therapeutic regimen establishment and prognosis evaluation in patients with moderate or high risk, our present review is going to summarize the relevant data about the bio-chemical characteristics of Lp-PLA(2), the actions of Lp-PLA(2) on atherosclerosis and the results of Lp-PLA(2) in scientific research and clinical studies."
|3.||Coronary Disease (Coronary Heart Disease)
03/01/2011 - "This study sought to determine the relation between and discriminative capability of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and coronary heart disease (CHD) in a large population of disease-free women. "
01/01/2012 - "Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies."
03/04/2008 - "Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study."
08/01/2005 - "Although epidemiology studies consistently support a relationship between plasma Lp-PLA2 levels and susceptibility to coronary heart disease this is not the case for Lp-PLA2 polymorphisms. "
04/01/2015 - "Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays an important role in coronary heart disease (CHD). "
02/01/2011 - "Studies on drapalib, which is a direct inhibitor of Lp-PLA2, have shown that Lp-PLA2 prevents necrotic core progression and reduces plaque inflammation. "
01/01/2007 - "We tested this hypothesis using samples from the San Antonio Family Heart Study that were assayed for activity of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), a marker of inflammation and oxidative stress. "
10/31/2000 - "Preclinical studies have demonstrated that recombinant plasma PAF acetylhydrolase can prevent or attenuate pathologic inflammation in a number of animal models. "
09/01/2015 - "Then, chronic inflammation was induced in an in vivo mouse model, resulting in an increase in Lp-PLA2 expression in peripheral blood mononuclear cells (PBMCs) and arteries. "
09/01/2015 - "ω3-PUFAs suppressed Lp-PLA2 expression; the suppression induced by docosahexaenoic acid (DHA) was related to reduced inflammation. "
|5.||Atherosclerotic Plaque (Atheroma)
06/01/2005 - "Initial clinical studies suggest that the inhibitors of Lp-PLA(2) can block enzyme activity in plasma and within atherosclerotic plaques. "
12/01/2015 - "PLA2G7 encodes Lp-PLA2 having role in the formation of atherosclerotic plaques by catalyzing its substrate, phosphatydilcholine (PC), to be pro-inflammatory substances. "
05/01/2014 - "Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. "
12/01/2013 - "Lipoprotein-associated phospholipase A2 (Lp-PLA2) might play a role in the formation of vulnerable atherosclerotic plaques. "
09/20/2013 - "Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory biomarker secreted in the atherosclerotic plaque. "
|4.||Secretory Phospholipases A2
|4.||Intensive Care (Surgical Intensive Care)